Rick Yang

Filings by Rick Yang span 6 companies, the busiest being NeueHealth, Inc., SpyGlass Pharma, Inc. and Monte Rosa Therapeutics, Inc. In total, 27 filings cover trades dated from 28 June 2021 to 10 March 2026.

In open-market terms, that means 6 purchases worth €40.4M on one side and 3 sales worth €21k on the other. On balance, insiders were net buyers of €40.4M. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The rest of the record consists of 5 share grants and 2 option exercises. 2026 to date brings 2 purchases and no sales.

In size, the median ticket on the buying side is €4.6M. On 6 out of 6 purchases, another insider of the same company was buying within the same 30 days. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.

The record was last updated on 12 March 2026 with an open-market purchase (€2.0M) in Korro Bio, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.